Mark December 5 on your calendar

| White Listing Instructions|

Dear Money Morning Reader, December 5, 2010. That day the FDA's trial results on a stunning new drug will become public. Right now, only a handful of people already know the results. Luckily, we're among the few. What will be reported on December 5th is this: That 16 of 21 patients saw their leukemia wiped out in this study. No traces left. It's an amazing success. It will be huge news at the American Society of Hematology's Annual Meeting in Orlando, FL on 12/5. Scientists will also announce that this drug "seems capable of eradicating chemotherapy-resistant tumor cells" and causes "long-lasting remissions." We've been following this drug development for over two years now - as well as the company that makes it. Shares of this company trade at under $7 today, yet estimates show they could run up to $140. Our special presentation has all the details. Just go here. But don't wait too long. Sincerely, Mike Ward Publisher, Money Morning P.S. It's not unusual to see a stock pop by 20%, 40%, even 100% on important clinical data or FDA trial results. So you'll want to act immediately. SPECIAL PRESENTATION HERE   Money Morning: You are receiving this e-mail as a part of your free subscription to The Money Morning E-Letter. Remove your email from this list: Unsubscribe To cancel by mail or for any other subscription issues, write us at: Money Morning Attn: Member Services 105 West Monument Street Baltimore, MD 21201 © 2010 Money Morning All Rights Reserved Money Morning· 105 West Monument Street · Baltimore, MD 21201 North America: 1 800 681 2581; Fax: 1 410 223 2650 International: +1 630 820 5053; Fax: +1 410 223 2650 Website: http://www.moneymorning.com Nothing in this e-mail should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Money Morning. 105 W. Monument Street, Baltimore MD 21201.   PLEASE DO NOT REPLY DIRECTLY TO THIS EMAIL. To contact us for any reason, see the notice at the bottom of this message. If you wish to contact us, please do not reply to this message but instead go to CustomerService@MoneyMorningInfo.com. Replies to this message will not be read or responded to. We look forward to your feedback and questions. However, the law prohibits us from giving individual and personal investment advice. We are unable to respond to emails and phone calls requesting that type of information.